Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

May 11, 2023

https://www.globenewswire.com/news-release/2023/05/11/2667052/0/en/Allogene-Therapeutics-Announces-Encore-Presentation-of-Phase-1-Data-from-the-ALLO-501-501A-Trials-in-Large-B-Cell-Lymphoma-at-the-European-Hematology-Association-EHA-Hybrid-Congres.html

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced an encore presentation of data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A at the European Hematology Association (EHA) Hybrid Congress on June 8–11, 2023 in Frankfurt, Germany.

Read more at globenewswire.com

Related news for (ALLO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.